Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis01:24

Disorders of Hemostasis

754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
Teratogenicity01:07

Teratogenicity

2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed ADAMTS13 normalisation in caplacizumab/PEX treated patients associated with anti-ADAMTS13 IgG antibody boosting.

Blood advances·2026
Same author

Refractoriness in TTP: challenges and solutions.

Blood·2026
Same author

Emerging from the shadows of congenital TTP.

Blood advances·2026
Same author

Thrombotic thrombocytopenic purpura: celebrating 25 years of ADAMTS13.

Blood·2026
Same author

Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura.

Blood·2025
Same author

Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.

British journal of haematology·2024
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
Same journal

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026
Same journal

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

British journal of haematology·2026
Same journal

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

British journal of haematology·2026
Same journal

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

778

TTP and pregnancy.

P Gounder1, M Scully1,2

  • 1Department of Haematology, UCLH, London, UK.

British Journal of Haematology
|August 28, 2024
PubMed
Summary
This summary is machine-generated.

Acute thrombocytopenic purpura (TTP) during pregnancy requires prompt diagnosis and treatment to prevent severe maternal and fetal complications. Differentiating immune from congenital TTP is crucial for effective management and future pregnancies.

Keywords:
TTPpregnancytreatment

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Accurate and Simple Evaluation of Vascular Anastomoses in Monochorionic Placenta using Colored Dye
09:52

Accurate and Simple Evaluation of Vascular Anastomoses in Monochorionic Placenta using Colored Dye

Published on: September 5, 2011

26.8K

Related Experiment Videos

Last Updated: Jun 15, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

778
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Accurate and Simple Evaluation of Vascular Anastomoses in Monochorionic Placenta using Colored Dye
09:52

Accurate and Simple Evaluation of Vascular Anastomoses in Monochorionic Placenta using Colored Dye

Published on: September 5, 2011

26.8K

Area of Science:

  • Hematology
  • Obstetrics
  • Reproductive Medicine

Background:

  • Acute thrombocytopenic purpura (TTP) can occur during pregnancy or the postpartum period.
  • Delayed diagnosis and treatment of TTP can lead to severe maternal and fetal complications.

Purpose of the Study:

  • To highlight the critical importance of timely diagnosis and management of TTP in pregnancy.
  • To discuss current and emerging therapeutic strategies for TTP in obstetric patients.
  • To emphasize the necessity of distinguishing between immune and congenital TTP for optimal patient care.

Main Methods:

  • Review of current literature on TTP in pregnancy.
  • Discussion of established treatments like plasma exchange and immunosuppression.
  • Exploration of novel therapies such as caplacizumab and recombinant ADAMTS13.

Main Results:

  • Prompt diagnosis and intervention are associated with improved maternal and fetal outcomes.
  • Plasma exchange and immunosuppression remain primary treatment modalities.
  • Emerging therapies show promise for TTP management.

Conclusions:

  • Effective management of TTP in pregnancy hinges on early recognition and appropriate therapy.
  • Distinguishing immune TTP from congenital TTP is essential for guiding treatment and counseling for future pregnancies.
  • Advances in TTP treatment offer new hope for improved outcomes in obstetric patients.